The carvedilol hibernation reversible ischaemia trial; marker of success (CHRISTMAS)

European Journal of Heart Failure

Volumn 1, Issue 2, 1999, Pages 191-196

  Cleland, John G F ^a   Pennel, Dudley ^a   Ray, Simon ^a   Murray, Gordon ^a   MacFarlane, Peter ^a   Cowley, Allan ^a   Coats, Andrew ^a   Lahiri, Avijit ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Beta blockers; Heart failure; Hibernating myocardium

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ECHOCARDIOGRAPHY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE PERFUSION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYOCARDIAL HIBERNATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCREENING TEST; SYSTOLE;

ADRENERGIC BETA-ANTAGONISTS; ADULT; CARBAZOLES; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MYOCARDIAL CONTRACTION; MYOCARDIAL STUNNING; PROPANOLAMINES; PROSPECTIVE STUDIES; RADIONUCLIDE VENTRICULOGRAPHY; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0033498214     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(99)00024-0     Document Type: Article

References (32)

1. Cleland J.G.F., Bristow M., Erdmann E., Remme W.J., Swedberg K., Waagstein F. Beta-blocking agents in heart failure. Should they be used and how? Eur Heart J. 17:1996;1629-1639.
2. Bristow M.R., Gilbert E.M., Abraham W.T., Adams K.T., Fowler M.B., Hershberger R.E., Kubo S.H., Narahara K.A., Ingersoll H., Krueger S., Young S., Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 94:1996;2807-2816.
3. MacMahon S., Sharpe N., Doughty R., Krum H., Tonkin A., Trotter A., Burton R., Garrett J., Lane G., Owensby D. et al. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet. 349:1997;375-380.
4. Doughty R.N., Whalley G.A., Gamble G., MacMahon S., Sharpe N. Left ventricular remodelling with carvedilol in patients with congestive heart failure due to ischemic heart disease. JACC. 29:1997;1060-1066.
5. Doughty R.N., Rodgers A., Sharpe N., MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure - a systematic overview of randomised controlled trials. Eur Heart J. 18:1997;560-565.
6. Heidenreich P.A., Lee T.T., Massie B.M. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomised trials. J Am Coll Cardiol. 30:1997;27-34.
7. Cleland J.G.F., Freemantle N., McGowan J., Clark A. The evidence for beta-blockers equals or surpasses that for ACE inhibitors in heart failure. Br Med J. 318:1999;824-825.
8. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., Shusterman N.H. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. New Engl J Med. 334:1996;1349-1355. for the US Carvedilol Study Group.
9. Design of the cardiac insufficiency bisoprolol study II (CIBIS II). Fundam Clin Pharmacol. 11:1997;138-142.
10. Rationale, design, and organisation of the metoprolol CR/XL randomised intervention trial in heart failure (MERIT-HF). Am J Cardiol. 80:1997;54J-58J.
11. Woodley S.L., Gilbert E.M., Anderson J.L., O'Connell J.B., Deitchman D., Yanowitz F.G., Mealey P.C. et al. B-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation. 84:1991;2426-2441.
12. Bristow M.R., O'Connell J.B., Gilbert E.M. et al. Dose-response of chronic B-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation. 89:1994;1632-1642.
13. Fisher M.L., Gottlieb S.S., Plotnick G., Greenberg N.L., Patten R.D., Bennett S.K. et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol. 23:1994;943-950.
14. Dilsizian V., Bonow R.O. Current diagnostic techniques of assessing myocardial viability in patients with hibernating and stunned myocardium. Circulation. 87:1993;1-20.
15. Rahimtoola S.H. Importance of diagnosing hibernating myocardium: How and in whom? JACC. 30:1997;1701-1706.
16. Vanoverschelde J.J., Wijns W., Depre C., Essamri B., Heyndrickx G.R., Borgers M., Bol A., Melin J.A. Mechanisms of chronic regional postischemic dysfunction in humans: New insights from the study of noninfarcted collateral-dependent myocardium. Circulation. 87:1993;1513-1523.
17. Paolisso G., Gambardella A., Marasso G. et al. Metabolic and cardiovascular benefits deriving from B-adrenergic blockade in chronic congestive heart failure. Am Heart J. 123:1992;103-110.
18. McGowan J, Cleland JGF. Carvedilol in heart failure: clinical trials in progress. Heart Fail Rev 1999;in press.
19. Feuerstein G.Z., Ruffolo R.R. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur Heart J. 16:1995;38-42.
20. Yue T., Wang X., Gu J.L., Ruffolo R.R.J., Feuerstein G.Z. Carvedilol, a new vasodilating beta-adrenoceptor blocker, inhibits oxidation of low-density lipoproteins by vascular smooth muscle cells and prevents leukocyte adhesion to smooth muscle cells. J Pharm Exp Therapeutics. 273:1995;1442-1449.
21. Kober L., Torp Pedersen C. Clinical characteristics and mortality of patients screened for entry into the Trandolapril Cardiac Evaluation (TRACE) study. Am J Cardiol. 76:1995;1-5.
22. Kober L., Torp Pedersen C., Carlsen J., Videbaek R., Egeblad H. An echocardiographic method for selecting high risk patients shortly after acute myocardial infarction, for inclusion in multi-centre studies (as used in the TRACE study). Eur Heart J. 15:1994;1616-1620.
23. 201Tl imaging for prognostic evaluation after myocardial infarction and thrombolysis. Circulation. 96:1997;2932-2937.
24. Bax J.J., Wijns W., Cornel J.H., Visser F.C., Boersma E., Fioretti P.M. Accuracy of currently available techniques for prediction of functional recovery after revascularisation in patients with left ventricular dysfunction due to chronic coronary artery disease: comparison of pooled data. JACC. 30:1997;1451-1456.
25. Lahiri A., Senior R. Evolving therapeutic concepts and imaging in ischaemic cardiomyopathy. J Nuc Cardiology. 5:1998;598-608.
26. Cleland J.G.F., Erdmann E., Ferrari R., Hess O.M., Poole Wilson P.A., Remme W.J., Riegger G., Soler Soler J., Swedberg K.B., Tavazzi L., Waagstein F., Dargie H.J., Kjekshus O.M., Pouleur H. Guidelines for the diagnosis of heart failure. Eur Heart J. 16:1995;741-751.
27. Remme W.J., Cleland J.G.F. et al. European Society of Cardiology: Guidelines for the management of heart failure. Eur Heart J. 18:1997;736-753.
28. Pagley P.R., Beller G.A., Watson D.D., Gimple L., Ragosta M. Improved outcome after coronary bypass surgery in patients with ischemic cardiomyopathy and residual myocardial viability. Circulation. 96:1997;793-800.
29. di Carli M.F., Asgarzadie F., Schelbert H.R. et al. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularisation in patients with ischemic cardiomyopathy. Circulation. 92:1995;3436-3444.
30. Milano C.A., White W.D., Smith L.R., Jones R.H., Lowe J.E., Smith P.K., Van-Trigt P. Coronary artery bypass in patients with severely depressed ventricular function. Annals of Thoracic Surgery. 56:1993;487-493.
31. Mickleborough L.L., Maruyama H., Takagi Y., Mohamed S., Sun Z., Ebisuzaki E. Results of revascularisation in patients with severe left ventricular dysfunction. Circulation. 92(Suppl. II):1995;II73-II79.
32. Langenburg S.E., Buchanan S.A., Blackbourne L.H., Scheri R.P., Sinclair K.N., Martinez J., Spotnitz W.D., Tribble C.G., Kron I.L. Predicting survival after coronary revascularisation for ischemic cardiomyopathy. Ann Thorac Surg. 60:1995;1193-1197.